Abstract
ABSTRACT Introduction The management of rectal cancer (RC) has evolved with the introduction of Total Mesorectal Excision Surgery (TME), use of Magnetic Resonance Imaging (MRI) for staging, changes in chemotherapy and radiotherapy and multidisciplinary meetings (MDTs). The timing of therapy for T3/4 and/or node positive RC has also changed with neoadjuvant chemoradiotherapy (CRT) becoming standard based on lower local recurrence rates. Given these changes in management over time, we assessed disease free survival (DFS), overall survival (OS) and rates of local and distant recurrences of patients treated at The Queen Elizabeth Hospital (TQEH) between 1992 to 2006. Method Demographic and outcome data of patients diagnosed with early stage RC from TQEH Cancer Registry from 2 different time cohorts 1992-99 (A) and 2000-06 (B) were analysed. Survival analysis was by Kaplan-Meier method and prognostic factors were analysed using cox proportional hazards regression. Results 423 patients were identified; 235 in A, 188 in B. Patient characteristics were generally similar. Median age A 68.1 yrs (range 32-94), B was 67.4 yrs (range 25-92). More patients had stage B in cohort A (47%) v B (39%). 56% of patients had surgery alone in cohort A compared to 47% in cohort B. Rates of any “adjuvant” therapy was similar (A = 41% v B = 46%), although there was a doubling in proportion of patients who received neoadjuvant CRT in the latter cohort (A= 7.2% v B= 16%). There was a significant improvement in rate of 5 year local/distal recurrence; A 87%/71% v B 95%/81%, p Conclusion There has been significant improvement in DFS, OS and local and distant recurrence rates in patients diagnosed with early stage RC. The trend to greater use of neoadjuvant CRT in the latter cohort is consistent with changes in practice, and this may be a factor in improved local control, but does not appear to impact on survival. Other factors likely to have improved overall outcomes include: increased TME rates, improved preoperative staging including use of MRI and potentially the introduction of MDTs. Disclosure All authors have declared no conflicts of interest.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.